



211232

00-000000000

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at . Please contact CVS/Caremark at 1-888-413-2723 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of the medication.

Patient Name: Patient ID: Patient Group No:				_ Date: Patient Date Of Birth:	7/17	7/17/2024				
		NPI#:		Patient Phone:	Spec	Physician Name: Specialty: Physician Office Telephone				
Phy	sician Office Address:									
Dru	Drug Name (specify drug)				_					
Quantity: Route of Administration: Diagnosis:				Expected Length of Therapy:						
Cor										
Plea	ase check the appropriate What is the diagnosis?	te answer	for each applica	ble question.						
	Homocystinuria (If ch	ecked, go t	0 2)							
	Methylmalonic aciden	nia with ho	mocystinuria (If c	hecked, go to 12)						
	Other, please specify. (If checked, no further questions)									
2.	Is this a request for conf	tinuation of	therapy?		Υ		N			
3.	Is the total homocystein	e level und	etectable or pres	ent only in small amounts?	Υ		N			
4.	Is there a substantial de	ecrease in h	nomocysteine leve	els?	Υ		N			
5.	Will the dose be increas undetectable or present	sed until ma in only sm	aximum tolerability all amounts?	y or plasma total homocysteine level i	s y		N			
6.	Does the patient have c	ystathionin	e beta-synthase	(CBS) deficiency?	Y		N			
7.	Will plasma methionine through dietary modifica	concentrat ation, and if	ions be monitored necessary, a red	d and kept below 1,000 micromol/L luction in dose for the requested drug	, Y		N			
8.	Will the requested drug	be used to	decrease elevate	ed homocysteine blood levels?	Υ		N			
9.	Does the patient have o	ne of the fo	ollowing types of I	nomocystinuria?						
	Yes, Cystathionine be	eta-synthas	e (CBS) deficiend	cy (If checked, go to 10)						
	Yes, 5,10-methylenet 11)	etrahydrofo	olate reductase (N	ATHFR) deficiency (If checked, go to						
	Yes, Cobalamin cofac	ctor metabo	olism (cbl) defect	(If checked, go to 11)						
	No, Other, please spe	ecify. (If che	ecked, no further	questions)						
10.	Will plasma methionine through dietary modifica	concentrat	ions be monitored necessary, a red	d and kept below 1,000 micromol/L luction in dose for the requested drug	, Y		N			

11.	Was the diagnosis confirmed by enzyme assay or genetic testing? ACTION REQUIRED: If Yes, please attach supporting documentation for the following: a) For cystathionine beta-synthase (CBS) deficiency, enzyme analysis of CBS activity or genetic testing results, b) For 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency, enzyme analysis of MTHFR activity or genetic testing results, or c) For cobalamin cofactor metabolism (cbl) defect, genetic testing results. ACTION REQUIRED: Submit supporting documentation	Y		N	
12.	Is this a request for continuation of therapy?	Y		N	
13.	Has the patient experienced benefit from therapy as evidenced by disease stability or disease improvement?	Υ		N	
and tr	st that the medication requested is medically necessary for this patient. I further attest that the information ue, and that the documentation supporting this information is available for review if requested by the clair uponsor, or, if applicable a state or federal regulatory agency.	n pro ns pr	vided is ac ocessor, t	ccura he he	te ealth

Prescriber (Or Authorized) Signature and Date

Now you can get responses to drug PAs immediately and securely online—without faxes, phone calls, or waiting. How? With electronic prior authorization (ePA)! For more information and to register, go to www.caremark.com/epa.